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Abstract 
A consistent feature of predictive testing guidelines for Huntington’s disease (HD) is the 
recommendation not to undertake predictive tests on those <18 years.  However, exceptions are 
made, but the extent of, and reasons for deviation from the guidelines are unknown. The UK 
Huntington’s Prediction Consortium has collected data annually on predictive tests undertaken from 
the 23 UK genetic centres in the UK. DNA analysis for HD in the Netherlands is centralized in the 
Laboratory for Diagnostic Genome Analysis.  In the UK, 60 tests were performed on minors between 
1994 and 2015 representing 0.63% of the total number of tests performed. In the Netherlands, 23 
tests were performed between 1997 and 2016. The majority of the tests were performed on those 
aged 17 and 16 years for both countries (57% and 23% for the UK, and 57% and 26% for the Dutch). 
Data on the reasons for testing were identified for 36 UK and 22 Dutch cases and included: close to 
the age of 18 years, pregnancy, currently in local authority care and likely to have less support 
available after 18 years, person never having the capacity to consent and other miscellaneous 
reasons. 
This study documents the extent of HD testing of minors in the UK and the Netherlands and suggests 
that, in general, the recommendation is being followed. We provide some empirical evidence as to 
reasons why clinicians have departed from the recommendation. We do not advise changing the 
recommendation but suggest that testing of minors continues to be monitored.  
 
Key words: Huntington’s disease, Predictive testing, minors. 
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Introduction  
 
Huntington’s disease (HD) is a well-known neurodegenerative disorder with age dependent 
penetrance1. Predictive testing for HD became available in 19862 and was initially undertaken as part 
of research projects; however, guidelines for predictive testing were developed and first published in 
1989 and 19903,4 and have since been updated twice5,6,7.  In the earlier versions the guidance was 
not to test before the age of majority but, the latest update specifically states that “…the minimum 
age of testing be 18 years. Minors at risk requesting the test should have access to genetic 
counselling, support and information including discussion of all their options for dealing with being 
at risk.”  Elsewhere in that document there is a comment that the recommendations are “not 
intended as rigid rules but rather recommendations to guide and inform practice, based on current 
evidence and expertise”7. The debate and recommendation not to test minors are based on 
theoretical concepts with limited empirical evidence available8-13.  In this report we document the 
extent of predictive testing for minors in the UK and the Netherlands, and comment on some of the 
reasons why clinicians have departed from the guidelines/recommendations. 
Methods 
 
Data Collection in the UK 
In the UK, a Huntington’s Prediction Consortium (UKHPC) was launched in 1989 to collect annually 
anonymised data on predictive tests for HD performed in the UK. This database has been described 
previously and has been used to present data on the uptake of predictive testing in the UK14.  We 
analysed data from 1994 because that was the first full year for which predictive testing was 
available based on measurement of the CAG repeat length. Given the strong and consistent 
recommendation not to test those <18 years, the few cases where this had occurred were not 
included in that report. We have now used the UKHPC database to report on the extent of predictive 
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testing of minors in the UK. Some reasons for predictive testing were noted on the database but, in 
addition, the UK clinical genetic centres were asked to give more detail on the reasons why a test 
was undertaken on a minor. This exercise resulted in two additional cases being reported. 
 
Data Collection in the Netherlands 
DNA analysis for HD in the Netherlands is centralized in the Laboratory for Diagnostic Genome 
Analysis (LDGA), Department of Clinical Genetics (Leiden Medical University Center, Leiden, The 
Netherlands). All requests for pre-symptomatic testing of minors were identified from patients who 
had undergone DNA analysis for HD between January 1997 and December 2016. The referring 
clinical geneticists were asked to give more detail on the reasons for testing. 
Results 
There are 23 genetic centres in the UK but not all centres reported data for every year. In the period 
1994-2015 there should have been 506 centre level annual reports (22 years x 23 centres) but in fact 
476 (95%) were reported. Testing of minors was reported from 20 of the 23 UK genetic centres. 
There were 9616 tests recorded on the database with 9466 having an age of testing recorded.  63 
tests were reported on patients <18 years but subsequently two entries were questioned and one 
entry was marked as already symptomatic. The extent of predictive testing of those <18 years in the 
UK is 60/9463 = 0.63%. An equivalent figure was not available for the Dutch data. The male/female 
ratio for the UK data was 21:39; similarly, the ratio of normal to abnormal results was 38:22. Neither 
ratio was significantly different from that seen in the UK adults having predictive tests14. The prior 
probability was 50% in 53 cases and 25% in 5 cases; in one case the prior probability was low 
because it was a re-test to confirm a previous pre-natal test result based on a linkage analysis and in 
a further case the prior probability was difficult to determine from the UKHPC database.  
Testing Minors for Huntington’s Disease  
 
5 
 
Some comments on the reasons for testing were recorded on the database but additionally centres 
were contacted to provide more detail on the reasons for the predictive test. This resulted in the 
description of two cases not recorded on the database. Reasons for testing 36 cases from the UK and 
22 from the Netherlands are summarised in Table 1. The age structure of predictive tests 
undertaken on minors in the UK and the Netherlands is shown in Fig 1; it can be seen that that most 
tests of minors were performed on those aged 16 and 17 years (23% and 57% respectively for the UK 
and 26% and 57% for the Netherlands). 
One of the additional cases reported from the UK was a boy with a maternal family history of HD and 
paternal family history of seizures. He had an unremarkable birth history but developed neonatal 
seizures at 5 days. By the age of 4 years he had evidence of developmental delay and intention 
tremor. An MRI scan showed normal basal ganglia but a small cerebellum was questioned. He had 
brisk lower limb reflexes and by the age of 5 years juvenile onset HD was considered. He was tested 
for HD and the result was normal.  
In the Dutch data, the male/female ratio was 8:11; the ratio of normal to abnormal results was 18:5. 
The former ratio was the same as seen in a series of Dutch adults having predictive tests from 2005-
2011 (102:141, unpublished data). The latter ratio however was significantly different from the data 
in adults: in a group of 107 individuals aged 18-40 years having predictive tests the ratio was 55:52. 
The prior probability was 50% in 21 cases and 25% in one case.  In one case the prior probability was 
low because of an intermediate allele in the mother. 
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Discussion 
 
The current guidance advising against predictive tests for HD of minors is based on theoretical 
concerns and expert opinion of experienced practitioners7. We have provided some empirical 
evidence for the extent of the predictive testing of minors in the UK as 0.63%. In both the UK and the 
Netherlands, the most common reason for testing a minor was that the young person was close to 
18 years and counselling sessions had been undertaken. Testing was also performed in a small 
number of cases in relation to a pregnancy. One small category of cases relates to a “looked after” 
young person in foster care, or some other form of institutional care, when more support may be 
available to them as a minor rather than waiting until he/she is 18 years when less support might be 
available. It has to be acknowledged that it is impossible to know if the young person would still 
request predictive testing after having left the “care” environment. We also noted cases where the 
young person had another condition (Down syndrome or autism) which meant that the ability to 
consent was impaired, and was expected to remain so irrespective of the age of testing; therefore, 
the basis for the testing was an assessment of the best interests of the young person. An unusual 
scenario which occurred more than once was that juvenile HD had occurred in the family and testing 
of a sibling was undertaken <18 years. Each such case has to be assessed individually.   
Another scenario which occurred more than once was that all sibs in a sibship requested to be 
tested pre-symptomatically at the same time, including one or two minors. Repeated attempts to 
exclude the minors from such “group based” testing were made but this led to strong feelings of 
isolation and not being part of the family dynamics. For the sake of the family system, predictive 
testing was undertaken in those cases after a careful counselling procedure. 
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We have reported one diagnostic test performed because the possibility of juvenile HD was raised. It 
was not reported to the database because it had been performed as a potentially diagnostic test but 
it illustrates that challenging scenarios occasionally arise in at-risk patients with neurological or 
behavioural problems. Such a “diagnostic” test could be predictive, and difficult to interpret, if the 
CAG repeat expansion was not in the range clearly associated with juvenile onset disease. 
In the Dutch series, not only were results skewed to abnormal, but in addition, half of expanded CAG 
repeat lengths were in the high range (48-56 repeats), associated with younger age at onset. In 
several files it was mentioned that the parent was young when he or she developed symptoms of 
HD. Given the early age of onset in their parent, offspring may feel a greater urge to know their own 
status at a younger age than offspring of a parent whose onset was in their mid-forties or later. They 
(or their caregivers) may also experience subtle changes in behaviour and executive functions at a 
younger age, and consequently question whether such changes represent the onset of symptoms at 
a younger age. This was the case in two minors in the Dutch series, who presented behavioural 
problems at the time of their request. 
In one case the testing procedure departed from the protocol as the request came from a paediatric 
 neurologist. The laboratory noticed this only after DNA analysis had been completed. After 
consultation, the results were sent to a clinical geneticist, who reported the results in the first 
contact with the family. In order to prevent recurrence of this difficult situation, the Dutch 
laboratory now keeps strictly to the rule that pre-symptomatic testing can only be ordered by a 
clinical geneticist and the reason for testing is checked with the referring clinician for all requests 
regarding minors (including apparently diagnostic ones).  
 The relatively small number of tests which have been undertaken, and the fact that the majority 
were performed on those aged 17 years, suggests that the guideline is generally being observed. It 
should be noted that both in the UK and the Netherlands a young person at age 16 years can be 
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presumed to have the capacity to consent 15, 16.  A significant weakness of this study is that we have 
no information on the longer term outcomes of the testing.  Recording of cases by the UKHPC is 
voluntary, with a high reporting rate, but we cannot be sure that all cases in the UK are submitted. 
This information was extracted from a large data set and the accompanying notes on the reasons for 
testing are frequently brief.  
In conclusion, we do not advocate that the guidelines are changed but rather that the practice of 
testing minors continues to be assessed carefully on a case by case basis. The reasons for testing 
outside the recommendation should be documented carefully. The practice of laboratories accepting 
referrals for HD predictive tests, and apparently diagnostic tests, on minors only from clinical 
geneticists appears reasonable. 
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Table 1  
Reasons for testing Number (UK and Dutch data 
combined) 
Close to age 18 years 25 
Pregnancy 6 
Currently in care and more support available <18 years 4 
Person never having the capacity to consent 2 
Siblings in the family with young onset HD 3 
Persistent requests age 15 and 16 years 4 
Mother had an intermediate result 2 
? psychiatric symptoms 3 
Confirm a prenatal test result based on linkage analysis 1 
Estranged father with HD, mother had mental health 
problem and the young person had been told he/she 
would die. 
 
1 
Tested posthumously because mother wanted to make 
sense of the death which was due to another illness 
1 
Tested same time as mother 1 
Diagnostic test but result normal 1 
Tested together with siblings > 18 years (family wanted to 
go through the process as one) 
3 
Testing procedure not according to protocol (persistent 
request from minor was granted by child neurologist, 
results were given by clinical geneticist) 
1 
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Figure 1 
Age structure of 60 predictive tests undertaken in the UK 1994-2015 
 and 23 in the Netherlands 1997-2016 
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Legend to Figure 1 
Light grey represents the UK predictive testing of minors 
Dark grey represents The Netherlands testing of minors 
